酒精相关性肝病治疗的新兴靶点:来自非酒精性脂肪性肝炎的启示
综述指出,有害饮酒所致酒精相关性肝病与代谢综合征相关NAFLD是全球最常见的两种肝病,控制各自危险因素是长期管理基石,且均无有效疗法。文章聚焦代谢靶点,梳理两者共有的脂代谢紊乱、细胞死亡与固有免疫细胞及星状细胞激活等通路,并区分肠道菌群、糖代谢与胰岛素抵抗、炎症信号及microRNA异常等各自独特通路,以提示潜在治疗靶点。
要点
- 酒精相关性肝病与NAFLD共享脂代谢紊乱、细胞死亡及固有免疫细胞和星状细胞激活等致病通路。
- 两者在肠道菌群改变、糖代谢与胰岛素抵抗、炎症信号及microRNA异常等通路上存在差异。
- 综述旨在拓宽对NAFLD已研究的代谢靶点的认识,并探讨其应用于酒精相关性肝病的可能。
核心结论
- 综述通过比较酒精相关性肝病与NAFLD的保守与独特致病通路,提示可用于两种疾病的潜在治疗靶点及各自独有的靶点。
研究设计与样本
- 综述类文章,检索范围未在摘要中报告。
主要发现
- 两种疾病共享脂代谢失调、包括凋亡在内的细胞死亡通路、固有免疫细胞激活及星状细胞介导等保守致病通路,导致脂肪变、炎症、纤维化及肝硬化等组织学异常。
- 肠道菌群改变、糖代谢与胰岛素抵抗、炎症信号及microRNA异常等通路在两种疾病中表现不同。
关键数值与推荐
- 原文未报告具体标准或数值。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Alcohol-associated liver disease due to harmful alcohol use and NAFLD associated with metabolic syndrome are the 2 most common liver diseases worldwide. Control of respective risk factors is the cornerstone in the long-term management of these diseases. Furthermore, there are no effective therapies. Both diseases are characterized by metabolic derangements; thus, the focus of this review was to broaden our understanding of metabolic targets investigated in NAFLD, and how these can be applied to alcohol-associated liver disease. Conserved pathogenic pathways such as dysregulated lipid metabolism, cell death pathways including apoptosis and activation of innate immune cells, and stellate cells mediate both alcohol and NAFLDs, resulting in histological abnormalities of steatosis, inflammation, fibrosis, and cirrhosis. However, pathways such as gut microbiome changes, glucose metabolism and insulin resistance, inflammatory signaling, and microRNA abnormalities are distinct in these 2 diseases. In this review article, we describe conserved and distinct pathogenic pathways highlighting therapeutic targets that may be of potential in both diseases and those that are unique to each disease.
引用
- Singal AK, Shah VH, Malhi H, et al. Emerging targets for therapy in ALD: Lessons from NASH. Hepatology. 2023. PMID: 36938877. doi:10.1097/HEP.0000000000000381
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。